Skip to main content

Table 2 Utility values of the health states [53, 54]

From: Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections

Health state

Utility

Source & calculation

PP1M

Stable: Adherent

0.865

Layperson sample

Stable: Non-adherent

0.865

Assumed equal to Stable: Adherent

Relapse: Hospitalization

0.479

Layperson sample

Relapse: Ambulatory care

0.479

Layperson sample

Death

0.000

Assumed 0.000

PP3M

Stable: Adherent

0.916

Layperson sample and added benefit for time between injections

Stable: Non-adherent

0.865

Assumed equal to Stable: Adherent

Relapse: Hospitalization

0.479

Layperson sample

Relapse: Ambulatory care

0.479

Layperson sample

Death

0.000

Assumed 0.000

Treatment Interruption

Stable: Adherent

0.865

Layperson sample

Stable: Non-adherent

0.865

Assumed equal to Stable: Adherent

Relapse: Hospitalization

0.479

Layperson sample

Relapse: Ambulatory care

0.479

Layperson sample

Death

0.000

Assumed 0.000

Utility decrements for adverse events

Acute EPS

0.291

Layperson sample (0.865–0.574)

Weight gain

0.086

Layperson sample (0.865–0.779)

Diabetes

0.153

Layperson sample (0.865–0.712)

  1. Abbreviations: PP1M, paliperidone palmitate once-monthly injection; PP3M, paliperidone palmitate three-monthly injection; EPS, Extrapyramidal Symptoms